RiverVest Venture Partners — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)Samir Gharib(Executive Officer)RICHARD KING(Executive Officer, Director)
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsAisling CapitalHealthCapAbingworthNorwest Venture PartnersOrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.